Apogenix’s asunercept shown to offer benefits in Phase II Covid-19 trial

Apogenix has reported data from the Phase II ASUNCTIS clinical trial where its immunotherapy candidate, asunercept, was shown to offer statistically significant benefits in hospitalised patients with Covid-19.

The multicentre, open-label trial analysed the safety and efficacy of asunercept in 435 moderate to severe Covid-19 patients.